BioNxt Advances with Rapid-Dissolving Drug Technology

BioNxt Solutions Inc., based in Vancouver, has reported significant progress in addressing dysphagia, a common issue affecting up to 40% of adults who struggle with swallowing pills. This problem, particularly severe in patients with autoimmune diseases like Multiple Sclerosis (MS) and Myasthenia Gravis (MG), often impacts treatment adherence negatively.

In response, BioNxt has developed a rapid-dissolving, "melt-in-your-mouth" thin-film technology. Recently, the company secured a national patent for this technology, marking a crucial step toward commercialization. The technology is designed to offer a more accessible and patient-friendly drug delivery option, especially in high-value autoimmune markets.

The first patent, covering BioNxt's BNT23001 sublingual cladribine film for MS and MG, is valid through 2043 and extends across eight member states, targeting a population of over 200 million. A comparative human bioequivalence study for the film is slated for early 2026, aiming to expedite approval processes.